Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + SOX with or without trastuzumab as neoadjuvant therapy for HER2-positive resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2200059173Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab, trastuzumab, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological complete remission rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200059173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059173.